Financiado en parte por Pharmavite, Genentech
Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival
Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 41 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Gobierno
- U.S. Department of Defense
- Gobierno
- Women's Health Initiative
- Empresa
- Pharmavite
- Gobierno
- National Institutes of Health
- Empresa
- Genentech
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Gobierno
- NHLBI NIH HHS
- Gobierno
- WHI NIH HHS
- Subvenciones
- National Institutes of Health (CA 34944); National Cancer Institute (CA-167552); National Cancer Institute (R01 CA138962); National Cancer Institute (K07CA148894); National Heart, Lung, and Blood Institute (R01 HL102122); National Cancer Institute (CA-49449); National Cancer Institute (CA130288); National Heart, Lung, and Blood Institute (R01 HL034595); National Cancer Institute (P01 CA087969); National Cancer Institute (UM1 CA186107); National Cancer Institute (R01CA124908); National Cancer Institute (CA-87969); National Cancer Institute (CA197735); National Cancer Institute (UM1-CA-167552); National Cancer Institute (R35CA197735); National Cancer Institute (R01-CA49449); U.S. Department of Defense (CA130288); National Cancer Institute (CA127003); National Institutes of Health (CA130288); National Cancer Institute (CA-186107); National Cancer Institute (R01 CA034944); National Heart, Lung, and Blood Institute (R01 HL026490); National Cancer Institute (R01‐CA049449); National Cancer Institute (P50-CA127003); Women's Health Initiative (24152); National Institutes of Health (N01-WH-2-2110); National Cancer Institute (UM1 CA182913); National Cancer Institute (R01 CA040360); Women's Health Initiative (N01WH22110); National Institutes of Health (24152); National Cancer Institute ([P01 CA87969); National Institutes of Health (R01 CA49449); National Institutes of Health (P01 CA 87969); National Institutes of Health (UM1 CA167552); National Institutes of Health (N01 WH022110); National Institutes of Health (P50-CA127003); National Institutes of Health (UM1‐CA‐186107); National Institutes of Health (CA 40360); National Institutes of Health (CA-167552); National Institutes of Health (HL 34595); National Institutes of Health (CA186107); National Institutes of Health (UM1 CA186107, P01 CA87969, and R01 CA49449); National Institutes of Health (CA 87969); National Institutes of Health (CA197735); National Institutes of Health (HL-26490)
Según 10 financiadores declarados.
Publicación
- Publicado
- 2016-06-21 · J Clin Oncol · vol. 34 · número 24 · págs. 2899–2905
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 51 citas · más que el 95% de estudios similares · 4.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 45 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Pancreatic and Hepatic Oncology Research · Medical Imaging Techniques and Applications
- Palabras clave
- Medicine, Internal medicine, Vitamin D and neurology, Gastroenterology, Proportional hazards model, Hazard ratio, Pancreatic cancer, Prospective cohort study, Body mass index, Cancer, Cohort, Diabetes mellitus, Cohort study, Confidence interval, Endocrinology
- MeSH
- humans, carcinoma, pancreatic ductal, pancreatic neoplasms, vitamin d, prognosis, proportional hazards models, cohort studies, prospective studies, aged, united states, female, male, biomarkers, tumor
20 autores
- Chen Yuan
- Zhi Rong Qian
- Ana Babić
- Vicente Morales‐Oyarvide
- Douglas Adam Rubinson
- Peter Kraft
- Kimmie Ng
- Ying Bao
- Edward L. Giovannucci
- Shuji Ogino
- Meir J. Stampfer
- John Michael Gaziano
- Howard D. Sesso
- Julie E. Buring
- Barbara B. Cochrane
- Rowan T. Chlebowski
- Linda G. Snetselaar
- JoAnn E. Manson
- Charles S. Fuchs
- Brian Matthew Wolpin
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored.
Patients and methods
We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient ≥ 30 ng/mL) by using Cox proportional hazards regression models adjusted for age, cohort, race and ethnicity, smoking, diagnosis year, stage, and blood collection month. We also evaluated 30 tagging single-nucleotide polymorphisms in the vitamin D receptor gene, requiring P < .002 (0.05 divided by 30 genotyped variants) for statistical significance.
Results
Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients (33%) were vitamin D insufficient. Compared with patients with insufficient levels, multivariable-adjusted HRs for death were 0.79 (95% CI, 0.48 to 1.29) for patients with relative insufficiency and 0.66 (95% CI, 0.49 to 0.90) for patients with sufficient levels (P trend = .01). These results were unchanged after further adjustment for body mass index and history of diabetes (P trend = .02). The association was strongest among patients with blood collected within 5 years of diagnosis, with an HR of 0.58 (95% CI, 0.35 to 0.98) comparing patients with sufficient to patients with insufficient 25(OH)D levels. No single-nucleotide polymorphism at the vitamin D receptor gene met our corrected significance threshold of P < .002; rs7299460 was most strongly associated with survival (HR per minor allele, 0.80; 95% CI, 0.68 to 0.95; P = .01).
Conclusion
We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.